1 – Immunostimulation Technology
TriMix – Boosting immune response through the dendritic cell pathway in a sustainable way
eTheRNA’s TriMix contains three naked mRNA molecules:
TriMix is unique in the way it uses these three mRNA molecules to induce the proliferation of T-cells into either mature helper T-cells or cytotoxic T-cells – the ultimate ‘soldiers’ of the immune system that fight cancer cells and infectious agents. By combining TriMix with tumor-specific antigens or neoantigens the patient’s dendritic cells are stimulated to produce a more potent and larger population of antigen specific cytotoxic and helper T-cells compared to tumor antigens alone.
eTheRNA is now turning this ex vivo approach into products that can be directly injected intranodally in the form of naked mRNA or intravenously, where the mRNA is packaged in lipid nanoparticles.
Lipid nanoparticles – intravenous administration of mRNA in a packaged form
2 – Oncolysis and tumor microenvironment modulating technology
Naked or packaged mRNA is delivered intratumorally directly into the patient’s tumor site, a direct access to the effector site of the therapy. This modality offers opportunities to develop tumor-lytic, tumor-modifying and immune stimulating products. Preliminary experiments with a tumor-lytic modality showed impressive anti-tumor responses in the injected as well as in the non-injected tumors.
© 2020 Etherna | Studio Hanswijk